Misplaced Pages

Thymectacin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by DavidTTTaylor (talk | contribs) at 14:55, 16 April 2013 (WPCleaner v1.27 - Square brackets not correct end (Fixed using WP:WCW)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 14:55, 16 April 2013 by DavidTTTaylor (talk | contribs) (WPCleaner v1.27 - Square brackets not correct end (Fixed using WP:WCW))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Thymectacin
Identifiers
IUPAC name
  • (2S)-methyl 2-((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H25BrN3O9P
Molar mass574.3185 g/mol g·mol
  (verify)

Thymectacin (NB-1011, NB-101, N--2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer prodrug of brivudine monophosphate. It developed by New Biotics and it has entered in phase I clinical trials for colon cancer.

References

  1. Wilson, RH (2006). "Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer". The Oncologist. 11 (9): 1018–1024. doi:10.1634/theoncologist.11-9-1018. PMID 17030644. {{cite journal}}: More than one of |author= and |last1= specified (help)


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: